中国医药研发对照标品提供商
Non-clinical Research-used Medicine Sample Provider
登录
注册 订药物标准品请用邮件联系我们
世界标品医药目录搜索(中英文):点击知道
   世界各国官方药品目录搜索(英文):点击知道        
   世界标品医药知识搜索(中英文):点击知道        
  美国药房 加拿大药房 英国药房 瑞士药房 澳大利亚药房 新西兰药房 香港药房 印度药房 新加坡药房 俄罗斯药房  法律的依据  
日本药房 德国药房 孟加拉药房 巴西药房 欧洲共同体药房 土耳其药房 以色列药房 法国药房 罗马尼亚药房 墨西哥药房 爱尔兰药房
荷兰药房 意大利药房 保加利亚药房 南非药房 芬兰药房 挪威药房  
当前本网站药物产品种数共 8063,其中处方药 7688,非处方药 259,保健品/医疗用具 116  未搜索到药品的查询定购
免费电话(中文客服)
电子邮箱
info.shijiebiaopin.com@gmail.com
shijiebiaopin@hotmail.com
QQ
2656512168,1586083059,1793093587
药品分类
抗癌药物
心血管系统药物
激素内分泌药物
作用于呼吸系统药物
作用于消化系统药物
泌尿生殖系统及泌乳药物
抗微生物药物
神经系统药物
作用于传出神经系统药物
影响血液及造血系统药物
生物药物
抗过敏药物
调节水、电解质药
维生素类及微量元素药物
皮肤科药物
眼科药物
耳鼻喉及口腔科药物
骨科药物
作用于免疫系统药物
抗疟疾药物
糖尿病
作用于代谢机制药物
保健药品
急性疾病
美容药物
妇科药物
肾移植
动物用药
抗病毒药物
造影剂
罕见病治疗药物
肝脏、胆囊性疾病
  1997年1月1日 至 今天(2019年01月23日)十年半间美国FDA批准上市的全部抗癌新药

编号 Drug
药品名称
Drug Trade Name
药品商品名称
Approved Use
批准用途
Manufacturer
Distributor
制造商/销售商
Approval Date
批准日期
1 abarelix Plenaxis depot For the palliative treatment of men with advanced symptomatic prostate cancer, in whom LHRH agonist therapy is not appropriate and who refuse surgical castration, and have one or more of the following: (1) risk of neurological compromise due to metastases, (2) ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or (3) severe bone pain from skeletal metastases persisting on narcotic analgesia Praecis 2003-11-25
2 aldesleukin Prokine Treatment of adults with metastatic melanoma Chiron 1998-01-09
3 Aldesleukin Proleukin Treatment of adults with metastatic renal cell carcinoma Chiron Corp 1992-05-05
4 Alemtuzumab Campath Accel. Approv. (clinical benefit not established) Campath is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Millennium and ILEX Partners, LP 2001-05-07
5 alitretinoin Panretin Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Ligand Pharmaceuticals 1999-02-02
6 allopurinol Zyloprim Patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. GlaxoSmithKline 1996-05-17
7 altretamine Hexalen Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination. US Bioscience 1990-12-26
8 amifostine Ethyol To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer US Bioscience 1995-12-08
9 amifostine Ethyol Accel. Approv. (clinical benefit not established) Reduction of platinum toxicity in non-small cell lung cancer US Bioscience 1996-03-15
10 amifostine Ethyol To reduce post-radiation xerostomia for head and neck cancer where the radiation port includes a substantial portion of the parotid glands. US Bioscience 1999-06-24
11 anakinra Kineret pediatric Use section of the US product label and to fulfill PMC #3 to assess the safety and efficacy of anakinra in pediatric patients with juvenile rheumatoid arthritis Amgen 2006-12-15
12 anastrozole Arimidex Accel. Approv. (clinical benefit not established) for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer AstraZeneca 2002-09-05
13 anastrozole Arimidex Conversion to regular approval for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer AstraZeneca 2005-09-16
14 anastrozole Arimidex Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. AstraZeneca Pharmaceuticals 1995-12-27
15 anastrozole Arimidex For first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. AstraZeneca Pharmaceuticals 2000-09-01
16 arsenic trioxide Trisenox Second line treatment of relapsed or refractory APL following ATRA plus an anthracycline. Cell Therapeutic 2000-09-25
17 asparaginase Elspar Therapy of patients with acute lymphocytic leukemia Merck 1978-01-10
18 Asparaginase Elspar ELSPAR is indicated in the therapy of patients with acute lymphocytic leukemia. This agent is useful primarily in combination with other chemotherapeutic agents in the induction of remissions of the disease in pediatric patients. Merck & Co, Inc 2002-08-01
19 azacitidine Vidaza For use for the treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia Pharmion 2004-05-19
20 azacitidine Vidaza indicated for treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia. Pharmion 2007-01-26
21 BCG Live TICE BCG Organon Teknika Corp 1998-08-21
22 bevacizumab Avastin Metastatic colon carcinoma Genentech 2006-06-20
23 bevacizumab Avastin FDA approved changed in the Avastin package insert regarding warning and dose and administration for Reversible Posterior Leukoencephalopathy Syndrome. Nasal septum perforation was also added as a serious adverse event. Genentech 2006-09-21
24 bevacizumab Avastin a first-line treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer in combination with platinum-based chemotherapy Genentech 2006-10-11
25 bevacuzimab Avastin First-line treatment of patients with metastatic carcinoma of the colon and rectum (in combination with intravenous 5-fluorouracil-based chemotherapy) Genentech 2004-02-26
26 bexarotene capsules Targretin For the treatment by oral capsule of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Ligand Pharmaceuticals 1999-12-29
27 bexarotene gel Targretin For the topical treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Ligand Pharmaceuticals 2000-06-28
28 bleomycin Blenoxane Bristol-Myers Squibb 1973-07-31
29 bleomycin Blenoxane Sclerosing agent for the treatment of malignant pleural effusion (MPE) and prevention of recurrent pleural effusions. Bristol-Myers Squibb 1996-02-20
30 bortezombi Velcade for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy Millennium 2006-12-08
31 bortezomib Velcade Accel. Approv. (clinical benefit not established) for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy Millenium 2003-05-13
32 bortezomib Velcade Conversion to regular approval for treatment of multiple myeloma patients who have received as least one prior therapy Millenium 2005-03-25
33 busulfan intravenous Busulfex Use in combination with cyclophoshamide as conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Orphan Medical, Inc 1999-02-04
34 busulfan oral Myleran Chronic Myelogenous Leukemia- palliative therapy GlaxoSmithKline 1954-06-26
35 calusterone Methosarb Pharmacia & Upjohn Company 1973-02-20
36 capecitabine Xeloda Accel. Approv. (clinical benefit subsequently established) Treatment of metastatic breast cancer resistant to both paclitaxel and an anthracycline containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents Roche 1998-04-30
37 capecitabine Xeloda Initial therapy of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5_FU/LV has not been demonstrated with Xeloda monotherapy. Roche 2001-04-30
38 capecitabine Xeloda Conversion to regular approval for treatment in combination with docetaxel of patients with metastatic breast cancer after failure of prior anthracycline containing chemotherapy Roche 2001-09-07
39 capecitabine Xeloda Adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred Roche 2005-06-15
40 carboplatin Paraplatin Palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Bristol-Myers Squibb 1989-03-03
41 carboplatin Paraplatin Initial chemotherapy of advanced ovarian carcinoma in combination with other approved chemotherapeutic agents. Bristol-Myers Squibb 1991-07-05
42 carmustine BCNU, BiCNU Bristol-Myers Squibb 1977-03-07
43 carmustine Gliadel Treatment of patients with malignant glioma undergoing primary surgical resection MGI Pharma 2003-02-25
44 carmustine with Polifeprosan 20 Implant Gliadel Wafer For use in addition to surgery to prolong survival in patients with recurrent glioblastoma multiforme who qualify for surgery. Guilford Pharmaceuticals Inc. 1996-09-23
45 celecoxib Celebrex Accel. Approv. (clinical benefit not established) Reduction of polyp number in patients with the rare genetic disorder of familial adenomatous polyposis. Searle 1999-12-23
46 cetuximab Erbitux Accel. Approv. (clinical benefit not established) for treatment of EGFR-expressing metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy (in combination with irinotecan); as a single agent, treatment of EGFR-expressing metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy Imclone 2004-02-12
47 cetuximab Erbitux For use in combination with radiation therapy (RT) for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) or as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed. Imclone 2006-03-01
48 chlorambucil Leukeran GlaxoSmithKline 1957-03-08
49 cisplatin Platinol Metastatic testicular-in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors whoc have already received appropriate surgical and/or radiotherapeutic procedures. An established combination therapy consists of Platinol, Blenoxane and Velbam. Bristol-Myers Squibb 1978-12-19
50 cisplatin Platinol Metastatic ovarian tumors - in established combination therapy with other approved chemotherapeutic agents: Ovarian-in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Platinol and Adriamycin. Platinol, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Platinol therapy. Bristol-Myers Squibb 1978-12-19
51 cisplatin Platinol as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments such as surgery and/or radiotherapy. Bristol-Myers Squibb 1993-04-22
52 cladribine Leustatin, 2-CdA Treatment of active hairy cell leukemia. R.W. Johnson Pharmaceutical Research Institute 1993-02-26
53 clofarabine Clolar Accel. Approv. (clinical benefit not established) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens Genzyme 2004-12-28
54 cyclophosphamide Cytoxan, Neosar Bristol-Myers Squibb 1959-11-16
55 cyclophosphamide Cytoxan Injection Bristol-Myers Squibb 1959-11-16
56 cyclophosphamide Cytoxan Injection Bristol-Myers Squibb 1987-04-29
57 cyclophosphamide Cytoxan Tablet Bristol-Myers Squibb 1987-04-29
58 cytarabine Cytosar-U Pharmacia & Upjohn Company 1969-06-17
59 cytarabine liposomal DepoCyt Accel. Approv. (clinical benefit not established) Intrathecal therapy of lymphomatous meningitis Skye Pharmaceuticals 1999-04-01
60 dacarbazine DTIC-Dome Bayer 1975-05-27
61 dactinomycin, actinomycin D Cosmegen Merck 1964-02-04
62 dactinomycin, actinomycin D dactinomycin, actinomycin D Merck 1964-12-10
63 dalteparin sodium Fragmin provides for the use of Fragmin (dalteparin sodium injection) for extended treatment of symptomatic venous thromboembolism (VTE) [proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE)] to reduce the recurrence of VTE in patients with cancer. Pharmacia & Upjohn 2007-05-01
64 darbepoetin alfa Aranesp for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. Amgen 2007-03-09
65 darbepoetin alfa Aranesp Amgen 2007-04-10
66 Darbepoetin alfa Aranesp Treatment of anemia associated with chronic renal failure. Amgen, Inc 2001-09-17
67 Darbepoetin alfa Aranesp Aranesp is indicated for the treatment of anemia in patients with non- myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. Amgen, Inc 2002-07-19
68 dasatinib Sprycel Chronic myelogenous leukemia Bristol Myers Squibb 2006-06-28
69 daunorubicin liposomal DanuoXome First line cytotoxic therapy for advanced, HIV related Kaposi's sarcoma. Nexstar, Inc. 1996-04-08
70 daunorubicin, daunomycin Daunorubicin Leukemia/myelogenous/monocytic/erythroid of adults/remission induction in acute lymphocytic leukemia of children and adults. Bedford Labs 1998-01-30
71 daunorubicin, daunomycin Cerubidine In combination with approved anticancer drugs for induction of remission in adult ALL. Wyeth Ayerst 1987-03-11
72 decitabine Dacogen for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. MGI PHARMA INC 2006-05-05
73 denileukin Ontak Seragen 0000-00-00
74 Denileukin diftitox Ontak Accel. Approv. (clinical benefit not established) treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor Seragen, Inc 1999-02-05
75 dexrazoxane Zinecard Accel. Approv. (clinical benefit subsequently established) Prevention of cardiomyopathy associated with doxorubicin administration Pharmacia & Upjohn Company 1995-05-26
76 dexrazoxane Zinecard Conversion to regular approval for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. It is not recommended for use with the initiation of doxorubicin therapy. Pharmacia & Upjohn Company 2002-10-31
77 docetaxel Taxotere Accel. Approv. (clinical benefit subsequently established) Treatment of patients with locally advanced or metastatic breast cancer who have progressed during anthracycline-based therapy or have relapsed during anthracycline-based adjuvant therapy. Aventis Pharmaceutical 1996-05-14
78 docetaxel docetaxel Conversion to regular approval - treatment of locally advanced or metastatic breast cancer which has progressed during anthracycline-based treatment or relapsed during anthracycline-based adjuvant therapy Aventis Pharmaceutical 1998-06-22
79 docetaxel Taxotere For locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Aventis Pharmaceutical 1999-12-23
80 docetaxel Taxotere for use in combination with cisplatin for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition cisplatin for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. Aventis Pharmaceutical 2002-11-27
81 docetaxel Taxotere For use in combination with prednisone as a treatment for patients with androgen independent (hormone refractory) metastatic prostate cancer Aventis Pharmaceutical 2004-05-19
82 docetaxel Taxotere For use in combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable nodepositive breast cancer Aventis Pharmaceutical 2004-08-18
83 docetaxel Taxotere for use in combination with cisplatin and fluorouracil for the induction treatment of patients with inoperable, locally advanced squamous cell carcinoma of the head and neck. Sanofi Aventis 2006-10-17
84 doxorubicin Adriamycin PFS For use in combination with cyclophosphamide as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer Pharmacia 2003-05-08
85 doxorubicin Adriamycin, Rubex Pharmacia & Upjohn Company 1974-08-07
86 doxorubicin Adriamycin PFS Injectionintravenous injection Antibiotic, antitumor agent. Pharmacia & Upjohn Company 1987-12-23
87 doxorubicin liposomal Doxil Conversion to regular approval for treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy Alza 2005-01-28
88 doxorubicin liposomal Doxil Accel. Approv. (clinical benefit not established) Treatment of AIDS-related Kaposi's sarcoma in patients with disease that has progressed on prior combination chemotherapy or in patients who are intolerant to such therapy. Sequus Pharmaceuticals, Inc. 1995-11-17
89 doxorubicin liposomal Doxil Accel. Approv. (clinical benefit not established) Treatment of metastatic carcinoma of the ovary in patient with disease that is refractory to both paclitaxel and platinum based regimens Sequus Pharmaceuticals, Inc. 1999-06-28
90 DROMOSTANOLONE PROPIONATE DROMOSTANOLONE Eli Lilly 1961-10-26
91 DROMOSTANOLONE PROPIONATE MASTERONE INJECTION SYNTEX 1964-10-08
92 eculizumab Soliris for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. Alexion 2007-03-16
93 Elliott's B Solution Elliott's B Solution Diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma. Orphan Medical, Inc 1996-09-27
94 epirubicin Ellence A component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. Pharmacia & Upjohn Company 1999-09-15
95 epirubicin hcl epirubicin hcl as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. Mayne 2006-09-15
96 epoetin alfa Epogen/Procrit is indicated for the treatment of anemia related to therapy with zidovudine in HIV-infected patients. EPOGEN® is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients. EPOGEN® is not indicated for the treatment of anemia in HIV-infected patients due to other factors such as iron or folate deficiencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately. Amgen 2007-03-09
97 Epoetin alfa epogen EPOGENB is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy. EPOGEND is indicated to decrease the need for transfusions in patients who will be receiving concomitant chemotherapy for a minimum of 2 months. EPOGENB is not indicated for the treatment of anemia in cancer patients due to other factors such as iron or folate deficiencies, hemolysis or gastrointestinal bleeding, which should be managed appropriately. Amgen, Inc 1999-07-26
98 Epoetin alfa epogen EPOGENB is indicated for the reatment of anemia related to therapy with zidovudine in HIV- infected patients. EPOGENB is indicated to elevate or maintain the red blood cell level (as manifested by the hematocrit or hemoglobin determinations) and to decrease the need for transfusions in these patients. EPOGEND is not indicated for the treatment of anemia in HIV-infected patients due to other factors such as iron or folate deficiencies, hemolysis or gastrointestinal bleeding, which should be managed appropriately. Amgen, Inc 1999-07-26
99 Epoetin alfa epogen EPOGENB is indicated for the treatment of anemic patients (hemoglobin > 10 to _< 13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. Amgen, Inc 1999-07-26
100 Epoetin alfa epogen EPOGEN is indicated for the treatment of anemia associated with CRF, including patients on dialysis (ESRD) and patients not on dialysis. Amgen, Inch 1999-07-26
101 erlotinib Tarceva For treatment of locally advanced or metastatic Non Small-Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapy regimen OSI 2004-11-18
102 erlotinib Tarceva For use in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer OSI 2005-11-02
103 estramustine Emcyt palliation of prostate cancer Pharmacia & Upjohn Company 1981-12-24
104 etoposide phosphate Etopophos Management of refractory testicular tumors, in combination with other approved chemotherapeutic agents. Bristol-Myers Squibb 1996-05-17
105 etoposide phosphate Etopophos Management of small cell lung cancer, first-line, in combination with other approved chemotherapeutic agents. Bristol-Myers Squibb 1996-05-17
106 etoposide phosphate Etopophos anagement of refractory testicular tumors and small cell lung cancer. Bristol-Myers Squibb 1998-02-27
107 etoposide, VP-16 Vepesid efractory testicular tumors-in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical, chemotherapeutic and radiotherapeutic therapy. Bristol-Myers Squibb 1983-11-10
108 etoposide, VP-16 VePesid In combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. Bristol-Myers Squibb 1986-12-30
109 etoposide, VP-16 Vepesid In combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer. Bristol-Myers Squibb 1986-12-30
110 exemestane Aromasin For adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN® for completion of a total of five consecutive years of adjuvant hormonal therapy Pharmacia 2005-10-05
111 exemestane Aromasin Treatment of advance breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. Pharmacia & Upjohn Company 1999-10-21
112 fentanyl citrate Fentora for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Cephalon 2006-09-25
113 Filgrastim Neupogen Decrease incidence of infection in patients with nonmyeloid malignancies Amgen, Inc 1991-02-20
114 Filgrastim Neupogen NEUPOGEN is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever. Amgen, Inc 1998-04-02
115 Filgrastim Neupogen NEUPOGEN is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation hemotherapy treatment of adults with AML. Amgen, Inc 1998-04-02
116 Filgrastim Neupogen NEUPOGEN is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, eg, febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation. Amgen, Inc 1998-04-02
117 floxuridine (intraarterial) FUDR Roche 1970-12-08
118 fludarabine Fludara Palliative treatment of patients with B-cell lymphocytic leukemia (CLL) who have not responded or have progressed during treatment with at least one standard alkylating agent containing regimen. Berlex Laboratories Inc. 1991-04-18
119 fluorouracil, 5-FU Adrucil prolong survival in combination with leucovorin ICN Puerto Rico 1962-04-25
120 fulvestrant Faslodex the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy IPR 2002-04-25
121 gefitinib Iressa Accel. Approv. (clinical benefit not established ) as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies AstraZenca 2003-05-05
122 gemcitabine Gemzar Treatment of patients with locally advanced (nonresectable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas. Indicated for first-line treatment and for patients previously treated with a 5-fluorouracil-containing regimen. Eli Lilly 1996-05-15
123 gemcitabine Gemzar For use in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer. Eli Lilly 1998-08-25
124 gemcitabine hcl Gemzar Ovarian cancer Lilly 2006-07-14
125 gemicitabine Gemzar For use in combination with paclitaxel for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated Lilly 2004-05-19
126 gemtuzumab ozogamicin Mylotarg Accel. Approv. (clinical benefit not established) Treatment of CD33 positive acute myeloid leukemia in patients in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy. Wyeth Ayerst 2000-05-17
127 goserelin acetate Zoladex AstraZeneca Pharmaceuticals 1995-12-18
128 goserelin acetate Zoladex Implant Palliative treatment of advanced breast cancer in pre- and perimenopausal women. AstraZeneca Pharmaceuticals 1995-12-18
129 histrelin acetate Histrelin implant For the palliative treatment of advanced prostate cancer Valera 2004-10-12
130 hydroxyurea Hydrea Bristol-Myers Squibb 1967-12-07
131 hydroxyurea Hydrea Decrease need for transfusions in sickle cell anemia Bristol-Myers Squibb 1998-02-25
132 Ibritumomab Tiuxetan Zevalin Accel. Approv. (clinical benefit not established) treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab refractory follicular non-Hodgkin’s lymphoma. IDEC Pharmaceuticals Corp 2002-02-19
133 idarubicin Idamycin For use in combination with other approved antileukemic drugs for the treatment of acute myeloid leukemia (AML) in adults. Adria Laboratories 1990-09-27
134 idarubicin Idamycin In combination with other approved antileukemic drugs for the treatment of acute non-lymphocytic leukemia in adults. Pharmacia & Upjohn Company 1997-02-17
135 ifosfamide IFEX Third line chemotherapy of germ cell testicular cancer when used in combination with certain other approved antineoplastic agents. Bristol-Myers Squibb 1988-12-30
136 imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) Initial therapy of chronic myelogenous leukemia Novartis 2001-05-10
137 imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) metastatic or unresectable malignant gastrointestinal stromal tumors Novartis 2002-02-01
138 Imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). Novartis 2002-02-01
139 imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) Initial treatment of newly diagnosed Ph+ chronic myelogenous leukemia (CML). Novartis 2002-12-20
140 imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) for treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic phase. Follow-up is limited. Gleevec is also indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival in patients with CML blast crisis, accelerated phase or chronic phase after failure of alpha interferon. Gleevec is also indicated for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) Novartis 2003-04-18
141 imatinib mesylate Gleevec Accel. Approv. (clinical benefit not established) Treatment of pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell transplant or who are resistant to interferon alpha therapy. Novartis 2003-05-20
142 imatinib mesylate Gleevec Conversion to regular approval for treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy Novartis 2003-12-08
143 imatinib mesylate Gleevec for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML). Novartis 2006-09-27
144 imatinib mesylate Gleevec single agent for the treatment of multiple indications Novartis 2006-10-19
145 interferon alfa 2a Roferon A Treatment of patients with hairy cell leukemia Roche 1986-06-04
146 interferon alfa 2a Roferon A Chronic phase, Philadelphia chromosome positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis) Roche 1995-10-19
147 Interferon alfa-2a Roferon-A Hoffmann-La Roche Inc 1996-11-01
148 Interferon alfa-2b Intron A Interferon alfa-2b, recombinant for Injection is indicated for the treatment of patients 18 years of age or older with hairy cell leukemia. Schering Corp 1986-06-04
149 Interferon alfa-2b Intron A Interferon alfa-2b, recombinant for Injection is indicated for intralesional treatment of selected patients 18 years of age or older with condylomata acuminata involving external surfaces of the genital and perianal areas. Schering Corp 1988-06-06
150 Interferon alfa-2b Intron A Interferon alfa-2b, recombinant for injection is indicated for the treatment of selected patients 18 years of age or older with AIDS-related Kaposi's Sarcoma. The likelihood of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune system as indicated by total CD4 count. Schering Corp 1988-11-21
151 Interferon alfa-2b Intron A Interferon alfa-2b, recombinant for injection is indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence within 56 days of surgery. Schering Corp 1995-12-05
152 Interferon alfa-2b Intron A Interferon alfa-2b, recombinant for Injection is indicated for the initial treatment of clinically aggressive follicular non-Hodgkin’s Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older. Schering Corp 1997-11-06
153 Interferon alfa-2b Intron A Intron A Schering Corp 2002-06-21
154 irinotecan Camptosar Accel. Approv. (clinical benefit subsequently established) Treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy. Pharmacia & Upjohn Company 1996-06-14
155 irinotecan Camptosar Conversion to regular approval - treatment of metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy. Pharmacia & Upjohn Company 1998-10-22
156 irinotecan Camptosar For first line treatment n combination with 5-FU/leucovorin of metastatic carcinoma of the colon or rectum. Pharmacia & Upjohn Company 2000-04-20
157 lapatinib ditosylate Tykerb for use in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. SmithKline Beecham 2007-03-13
158 lapatinib ditosylate Tykerb mithKline Beecham 2007-04-27
159 lenalidomide Revlimid Multiple myeloma Celegene 2006-06-29
160 lenalidomide Revlimid for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities Celgene 2005-12-27
161 letrozole Femara Treatment of advanced breast cancer in postmenopausal women. Novartis 1997-07-25
162 letrozole Femara First-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Novartis 2001-01-10
163 letrozole Femara Novartis 2003-01-17
164 letrozole Femara Accel. Approv. (clinical benefit not established) for the extended adjuvant treatment of early breast cancer in postmenopausal women who have received five years of adjuvant tamoxifen therapy. Novartis 2004-10-29
165 leucovorin Wellcovorin, Leucovorin Leucovorin calcium is indicated fro use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Immunex Corporation 1952-06-20
166 leucovorin Leucovorin Immunex Corporation 1987-01-30
167 leucovorin Leucovorin Immunex Corporation 1987-01-30
168 leucovorin Leucovorin Immunex Corporation 1988-08-31
169 leucovorin Leucovorin n combination with fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Lederle Laboratories 1991-12-12
170 Leuprolide Acetate Eligard palliative treatment of advanced prostate cancer. QLT USA 2002-01-23
171 levamisole Ergamisol Adjuvant treatment in combination with 5-fluorouracil after surgical resection in patients with Dukes' Stage C colon cancer. Janssen Research Foundation 1990-06-18
172 lomustine, CCNU CeeBU Bristol-Myers Squibb 1976-08-04
173 meclorethamine, nitrogen mustard Mustargen Merck 1949-03-15
174 megestrol acetate Megace Bristol-Myers Squibb 1971-08-18
175 melphalan, L-PAM Alkeran GlaxoSmithKline 1964-01-17
176 melphalan, L-PAM Alkeran Systemic administration for palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. GlaxoSmithKline 1992-11-18
177 mercaptopurine, 6-MP Purinethol GlaxoSmithKline 1953-09-11
178 mesna Mesnex Prevention of ifosfamide-induced hemorrhagic cystitis Asta Medica 1988-12-30
179 mesna Mesnex tabs Reducing the incidence of ifosfamide-induced hemorrhagic cystitis Baxter 2002-03-21
180 methotrexate Methotrexate Lederle Laboratories 1953-12-07
181 methotrexate Methotrexate Lederle Laboratories 1959-08-10
182 methotrexate Methotrexate Lederle Laboratories 1971-11-01
183 methotrexate Methotrexate Lederle Laboratories 1971-11-01
184 methotrexate Methotrexate osteosarcoma Lederle Laboratories 1988-04-07
185 methotrexate Methotrexate Lederle Laboratories 1988-10-31
186 methoxsalen Uvadex For the use of UVADEX with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment. Therakos 1919-02-25
187 mitomycin C Mutamycin Bristol-Myers Squibb 1974-05-28
188 mitomycin C Mitozytrex therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Supergen 2002-11-14
189 mitotane Lysodren Bristol-Myers Squibb 1970-07-08
190 mitoxantrone Novantrone For use in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Immunex Corporation 1996-11-13
191 mitoxantrone Novantrone For use with other approved drugs in the initial therapy for acute nonlymphocytic leukemia (ANLL) in adults. Lederle Laboratories 1987-12-23
192 nandrolone phenpropionate Durabolin-50 Organon 1959-10-30
193 nelarabine Arranon Accel. Approv. (clinical benefit not established) for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens GlaxoSmithKline 2005-10-28
194 Nofetumomab Verluma Boehringer Ingelheim Pharma KG (formerly Dr. Karl Thomae GmbH) 1996-08-20
195 Oprelvekin Neumega Prevention of severe thrombocytopenia following myelosuppressive chemotherapy Genetics Institute, Inc 1997-11-25
196 Oprelvekin Neumega Genetics Institute, Inc 2002-09-18
197 Oprelvekin Neumega Neumega is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. Genetics Institute, Inc 2002-09-18
198 oprelvekin Neumega warnings regarding ophthalmologic and ventricular arrhythmias adverse events have been added to the oprelvekin (Neumega) label Wyeth 2006-09-13
199 oxaliplatin Eloxatin Accel. Approv. (clinical benefit not established) in combination with infusional 5-FU/LV, is indicated for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/LV and irinotecan. Sanofi Synthelabo 2002-08-09
200 oxaliplatin Eloxatin Conversion to regular approval for use in combination with infusional 5-Fluorouracil (5-FU) and Leucovorin (LV) for the treatment of patients previously untreated for advanced colorectal cancer Sanofi Synthelabo 2004-01-09
201 oxaliplatin Eloxatin for use in combination with infusional 5-FU/LV, for the adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor Sanofi Synthelabo 2004-11-04
202 paclitaxel Abraxane for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Abraxis 2007-02-15
203 paclitaxel Paxene treatment of advanced AIDS-related Kaposi's sarcoma after failure of first line or subsequent systemic chemotherapy Baker Norton Pharmaceuticals, Inc 1997-12-24
204 paclitaxel Taxol Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. Bristol-Myers Squibb 1992-12-29
205 paclitaxel Taxol Treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Bristol-Myers Squibb 1994-04-13
206 paclitaxel Taxol New dosing regimen for patients who have failed initial or subsequent chemotherapy for metastatic carcinoma of the ovary Bristol-Myers Squibb 1994-06-22
207 paclitaxel Taxol second line therapy for AIDS related Kaposi's sarcoma. Bristol-Myers Squibb 1997-08-04
208 paclitaxel Taxol For first-line therapy for the treatment of advanced carcinoma of the ovary in combination with cisplatin. Bristol-Myers Squibb 1998-04-09
209 paclitaxel Taxol for use in combination with cisplatin, for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Bristol-Myers Squibb 1998-06-30
210 paclitaxel Taxol For the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination therapy. Bristol-Myers Squibb 1999-10-25
211 paclitaxel Taxol First line ovarian cancer with 3 hour infusion. Bristol-Myers Squibb 2000-06-20
212 paclitaxel protein-bound particles Abraxane For the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracyline unless clinically contraindicated AM Bioscience 2005-01-07
213 palifermin Kepivance Decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoetic stem cell support Amgen 2004-12-15
214 pamidronate Aredia Treatment of osteolytic bone metastases of breast cancer in conjunction with standard antineoplastic therapy. Novartis 1998-09-22
215 panitumumab Vectibix to treat metastatic colorectal carcinoma Amgen 2006-09-27
216 pegademase Adagen (Pegademase Bovine) Enzyme replacement therapy for patients with severe combined immunodeficiency asa result of adenosine deaminase deficiency. Enzon 1990-03-21
217 pegaspargase Oncaspar Acute lymphoblastic leukemia Enzon 2006-07-24
218 pegaspargase Oncaspar Acute lymphocytic leukemia in L-asparaginase hypersensitive patients Enzon, Inc 1994-02-01
219 Pegfilgrastim Neulasta Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Amgen, Inc 2002-01-31
220 Peginterferon alfa-2b PegIntron trade name from PEG-Intron to PegIntron Schering 2006-12-22
221 pemetrexed disodium Alimta For use in the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery Lilly 2004-02-04
222 pemetrexed disodium Alimta Accel. Approv. (clinical benefit not established) as a single agent for the treatment of patients with locally advanced or metastatic non-small lung cancer after prior chemotherapy Lilly 2004-08-19
223 pentostatin Nipent Single agent treatment for adult patients with alpha interferon refractory hairy cell leukemia. Parke-Davis Pharmaceutical Co. 1991-10-11
224 pentostatin Nipent Single-agent treatment for untreated hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. (Supplement for front -line therapy.) Parke-Davis Pharmaceutical Co. 1993-09-29
225 pipobroman Vercyte Abbott Labs 1996-07-01
226 plicamycin, mithramycin Mithracin Pfizer Labs 1970-05-05
227 porfimer sodium Photofrin For the ablation of high-grade dysplasia in Barrett’s esophagus patients who do not undergo esophagectomy Axcan Scandipharm 2003-08-01
228 porfimer sodium Photofrin For use in photodynamic therapy (PDT) for palliation of patients with completely obstructing esophageal cancer, or patients with partially obstructing esophageal cancer who cannot be satisfactorily treated with ND-YAG laser therapy. QLT Phototherapeutics Inc. 1995-12-27
229 porfimer sodium Photofrin For use in photodynamic therapy for treatment of microinvasive endobronchial nonsmall cell lung cancer in patients for whom surgery and radiotherapy are not indicated. QLT Phototherapeutics Inc. 1998-01-09
230 porfimer sodium Photofrin For use in photodynamic therapy (PDT) for reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobroncial nonsmall cell lung cancer (NSCLC). QLT Phototherapeutics Inc. 1998-12-22
231 procarbazine Matulane Sigma Tau Pharms 1969-07-22
232 quinacrine Atabrine Abbott Labs 1964-12-07
233 Rasburicase Elitek ELITEK is indicated for the initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. Sanofi-Synthelabo, Inc 2002-07-12
234 rituximab Rituxan for the first-line treatment of patients with low grade or follicular, CD20-positive B-cell non-Hodgkin’s lymphoma. Genentech 2006-09-29
235 rituximab Rituxan for the first-line treatment of patients with low grade or follicular, CD20-positive B-cell non-Hodgkin’s lymphoma. Genentech 2006-09-29
236 Rituximab Rituxan Treatment of patients with relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma Genentech, Inc 1997-10-26
237 Rituximab Rituxan non-Hodgkin's lymphoma Genentech, Inc 2006-02-10
238 sargramostim Leukine Acceleration of myeloid recovery following autologous bone marrow transplant in patients with non-Hodgkin's lymphoma, acute lymphocytic leukemia, or Hodgkin's disease Berlex 1991-03-05
239 Sargramostim Prokine Immunex Corp 1996-10-07
240 sorafenib Nexavar For the treatment of patients with advanced renal cell carcinoma Bayer 2005-12-20
241 streptozocin Zanosar Antineoplastic agent. Pharmacia & Upjohn Company 1983-05-07
242 sunitinib Sutent for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate; for the treatment of advanced renal cell carcinoma. CP Pharmaceuticals 2007-02-02
243 sunitinib maleate Sutent treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate Pfizer 2006-01-26
244 sunitinib maleate Sutent Accel. Approv. (clinical benefit not established) for the treatment of advanced renal cell carcinoma. Approval for advanced renal cell carcinoma is based on partial response rates and duration of responses. There are no randomized trials of SUTENT demonstrating clinical benefit such as increased survival or improvement in disease-related symptoms in renal cell carcinoma. Pfizer 2006-01-26
245 talc Sclerosol For the prevention of the recurrence of malignant pleural effusion in symptomatic patients. Bryan 1997-12-24
246 tamoxifen Nolvadex AstraZeneca Pharmaceuticals 1977-12-30
247 tamoxifen Nolvadex As a single agent to delay breast cancer recurrence following total mastectomy and axillary dissection in postmenopausal women with breast cancer (T1-3, N1, M0) AstraZeneca Pharmaceuticals 1986-12-03
248 tamoxifen Nolvadex For use in premenopausal women with metastatic breast cancer as an alternative to oophorectomy or ovarian irradiation AstraZeneca Pharmaceuticals 1989-03-16
249 tamoxifen Nolvadex For use in women with axillary node-negative breast cancer adjuvant therapy. AstraZeneca Pharmaceuticals 1990-06-21
250 tamoxifen Nolvadex Metastatic breast cancer in men. AstraZeneca Pharmaceuticals 1993-04-01
251 tamoxifen Nolvadex Equal bioavailability of a 20 mg Nolvadex tablet taken once a day to a 10 mg Nolvadex tablet taken twice a day. AstraZeneca Pharmaceuticals 1994-03-21
252 tamoxifen Nolvadex to reduce the incidence of breast cancer in women at high risk for breast cancer AstraZeneca Pharmaceuticals 1998-10-29
253 tamoxifen Nolvadex In women with DCIS, following breast surgery and radiation, Nolvadex is indicated to reduce the risk of invasive breast cancer. AstraZeneca Pharmaceuticals 2000-06-29
254 temozolomide Temodar Accel. Approv. (clinical benefit not established) Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse with disease progression on a nitrosourea and procarbazine containing regimen Schering 1999-08-11
255 temozolomide Temodar Conversion to regular approval for the treatment of patients with newly diagnosed high grade gliomas concomitantly with radiotherapy and then as adjuvant treatment Schering 2005-03-15
256 teniposide, VM-26 Vumon In combination with other approved anticancer agents for induction therapy in patients with refractory childhood acute lymphoblastic leukemia (all). Bristol-Myers Squibb 1992-07-14
257 testolactone Teslac Bristol-Myers Squibb 1969-06-03
258 testolactone Teslac Bristol-Myers Squibb 1970-05-27
259 thalidomide Thalomid Multiple myeloma Celgene 2006-05-26
260 thioguanine, 6-TG Thioguanine GlaxoSmithKline 1966-01-18
261 thiotepa Thioplex Immunex Corporation 1959-03-09
262 thiotepa Thioplex Immunex Corporation 1994-12-22
263 thiotepa Thioplex Lederle Laboratories 1990-08-15
264 topotecan Hycamtin Treatment of patients with metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. GlaxoSmithKline 1996-05-28
265 topotecan Hycamtin Treatment of small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the phase 3 study) or at least 90 days (in the phase 2 studies) after chemotherapy GlaxoSmithKline 1998-11-30
266 topotecan hcl Hycamtin Cervical carcinoma GlaxoSmithKline 2006-06-14
267 toremifene Fareston Treatment of advanced breast cancer in postmenopausal women. Orion Corp. 1997-05-29
268 Tositumomab Bexxar Accel. Approv. (clinical benefit not established) Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy Corixa Corporation 2003-06-27
269 Tositumomab/I-131 tositumomab Bexxar Expand the indication to include patients with relapsed or refractory low grade follicular transformed CD20-positive non-Hodgkin's lymphoma who have not received rituximab GlaxoSmithKline 2004-12-22
270 trastuzumab Herceptin Early Stage Breast Cancer After Primary Therapy Genentech 2006-11-16
271 Trastuzumab Herceptin HERCEPTIN as a single agent is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have received one or more chemotherapy regimens for their metastatic disease. Genentech, Inc 1998-09-25
272 Trastuzumab Herceptin Herceptin in combination with paclitaxel is indicated for treatment of patients with metastatic breast cancer whose tumors overexpress the HER-2 protein and had not received chemotherapy for their metastatic disease Genentech, Inc 2000-02-09
273 Trastuzumab Herceptin Genentech, Inc 2002-08-28
274 Trastuzumab Herceptin Genentech, Inc 2002-08-28
275 tretinoin, ATRA Vesanoid Induction of remission in patients with acute promyelocytic leukemia (APL) who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens. Roche 1995-11-22
276 Uracil Mustard Uracil Mustard Capsules Roberts Labs 1962-09-13
277 valrubicin Valstar For intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Anthra --> Medeva 1998-09-25
278 vinblastine Velban Eli Lilly 1965-11-05
279 vincristine Oncovin Eli Lilly 1963-07-10
280 vincristine Oncovin Eli Lilly 1963-07-10
281 vincristine Oncovin Eli Lilly 1963-07-10
282 vincristine Oncovin Eli Lilly 1963-07-10
283 vincristine Oncovin Eli Lilly 1963-07-10
284 vincristine Oncovin Eli Lilly 1963-07-10
285 vincristine Oncovin Eli Lilly 1963-07-10
286 vinorelbine Navelbine Single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). GlaxoSmithKline 1994-10-23
287 vinorelbine Navelbine Navelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unreseactable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, Navelbine is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, Navelbine is indicated in combination with cisplatin. GlaxoSmithKline 2002-11-05
288 vorinostat Zolinza for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following two systemic therapies. Merck 2006-10-06
289 zoledronate Zometa the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy Novartis 2002-02-22
290 zoledronic acid Zometa Treatment of hypercalcemia of malignancy Novartis 2001-08-20
themecategory
 
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com,Inc., All rights Reserved
www.ShiJieBiaoPin.com, Inc.

客服工作时间:
太平洋时间18:00-24:00

加拿大免费电话:
 
友情提示:
以上电话为免费电话,无需您承担任何费用,世界药房提供中文客服,请您放心拨打!

美国付费电话:

 

香港付费电话:

   
电子邮件: info.shijiebiaopin.com@gmail.com